Apr 15, 2019 / 08:15PM GMT
Operator
Good day, ladies and gentlemen. Welcome to the SCYNEXIS Ibrexafungerp ECCMID 2019 Clinical Data Presentations Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded.
At this time, I would now like to turn the call over to Dr. Marco Taglietti, President and Chief Executive Officer of SCYNEXIS.
Marco Taglietti - SCYNEXIS, Inc. - CEO, President & Director
Thank you, operator. Welcome, and thank you for joining us to discuss the exciting new clinical data surrounding our lead product candidate, ibrexafungerp, that is being presented during the 29th European Congress of Clinical Microbiology Infectious Diseases or ECCMID in Amsterdam.
Let me remind you that during this call, we will be making forward-looking statements based on current expectations. Please refer to our SEC filings and detailed risk factors for further information. ECCMID is an important meeting for us given the exciting ibrexafungerp results. Across a total of 6 presentations, data we share that provide additional evidence of the potent
SCYNEXIS Inc to Discuss the Ibrexafungerp Data Presented at ECCMID 2019 - Conference Call Transcript
Feb 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers